Pars plana vitrectomy, vitreous hemorrhage, and tractional retinal detachment may be more likely after monotherapy with panretinal photocoagulation (PRP) vs anti-VEGF agents for proliferative diabetic retinopathy (PDR). Source: AAO
Traditionally, adults with esotropia who are treated with bilateral medial rectus recessions usually receive doses based on Marshall Parks’ tables; however, patients undergoing these surgeries for divergence insufficiency-type esotropia may need larger doses. Source: AAO
Subthreshold micropulse laser therapy and half-dose photodynamic therapy appear to yield similar 12-month outcomes in the treatment of chronic central serous chorioretinopathy. Source: AAO
Handheld OCT has the potential to simplify the evaluation of children with infantile nystagmus and diagnose retinal abnormalities without the use of more invasive procedures. Source: AAO
In patients with diabetes, GLP-1 agonists can help manage blood sugar levels but they might also be associated with higher odds of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME). Source: AAO
Traumatic cataract can appear long after injuries received in battle, diabetic retinopathy is increasing among US adults below the age of 40, and children with Down syndrome may not be as prone to uveitis as previously thought. Source: AAO
Though the risk of endophthalmitis was low overall, this large-scale study among Medicare recipients saw much higher odds associated with penetrating keratoplasty and anterior lamellar keratoplasty. Source: AAO
Some children with amblyopia may derive more benefit from high-intensity early eye patching than from an extended period of wearing eyeglasses prior to patching. Source: AAO
While an abnormal optic nerve MRI is almost always clinically significant, T2 hyperintensity or atrophy can be seen in conjunction with a variety of conditions, not just optic neuritis. Source: AAO
This is the first published study to report the outcomes of strabismic diplopia surgery in patients with thyroid eye disease who have undergone a course of teprotumumab therapy. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
